Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Net Income (2016 - 2025)

Fennec Pharmaceuticals' Net Income history spans 15 years, with the latest figure at $2.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 242.11% year-over-year to $2.1 million, compared with a TTM value of -$2.8 million through Dec 2025, down 1651.93%, and an annual FY2025 reading of -$9.7 million, down 180.8% over the prior year.
  • Net Income for Q4 2025 was $2.1 million at Fennec Pharmaceuticals, up from -$623000.0 in the prior quarter.
  • The five-year high for Net Income was $12.9 million in Q1 2024, with the low at -$8.0 million in Q3 2022.
  • Average Net Income over 5 years is -$2.9 million, with a median of -$3.9 million recorded in 2021.
  • Biggest YoY gain for Net Income was 316.58% in 2024; the steepest drop was 222.47% in 2024.
  • Tracing FENC's Net Income over 5 years: stood at -$4.2 million in 2021, then crashed by 63.58% to -$6.9 million in 2022, then soared by 62.03% to -$2.6 million in 2023, then skyrocketed by 42.67% to -$1.5 million in 2024, then surged by 242.11% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Net Income are $2.1 million (Q4 2025), -$623000.0 (Q3 2025), and -$3.2 million (Q2 2025).